""

Urothelial carcinoma of the urinary bladder (incl. renal pelvis, ureter)

Recruiting after consultation
Open recruiting

Neoadjuvant Therapy

There are currently no studies available

Adjuvant Therapy

Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG-Naïve Non-Muscle-Invasive Bladder Cancer Patients (POTOMAC)
Phase: III
Contact: Gabriele Bentz / Kontaktperson
Clinical Investigator: Dr. Gencay Hatiboglu
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT03528694
EudraCT-Number: (siehe EU klinisches Studienregister) 2017-002979-26

Metastatic Disease: First-Line-Therapy

Title: An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Phase: III
Contact: Stephanie Cordeiro de Lima / Study Nurse
Clinical Investigator: Dr. Stefanie Zschäbitz
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT04223856
EudraCT-Number: (siehe EU klinisches Studienregister) 2019-004542-15

Metastatic Disease: Follow-Up Treatment

There are currently no studies available

Surgical Study

There are currently no studies available

Radiotherapy Study

There are currently no studies available

Other study

There are currently no studies available